Measuring the Patient Health, Societal and Economic Benefits of US Pediatric Therapeutics Legislation

Author： Vernon John A.   Shortenhaus Scott H.  

Publisher： Adis International

ISSN： 1174-5878

Source： Pediatric Drugs, Vol.14, Iss.5, 2012-10, pp. : 283-294

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The economic burden of depression in the US: societal and patient perspectives

By Greenberg Paul E   Birnbaum Howard G  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 3, 2005-03 ,pp. : 369-376

Informa Healthcare

Access to resources Recommend Favorite

Equity, Access and Economic Evaluation in Rare Diseases: The Impact of Orphan Drug Legislation on Health Policy and Patient Care

By Bosanquet N.  

Pharmaceutical Development and Regulation, Vol. 1, Iss. 3, 2003-01 ,pp. : 151-157

Adis International

Access to resources Recommend Favorite

Societal benefits of telemedicine questioned

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 284, 2000-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Ethical, Political and Societal Implications of the Open Access Journal Movement in the Era of Economic Crisis, with Emphasis on Public Health Pharmacogenomics

By  

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 11, Iss. 4, 2013-12 ,pp. : 312-315

Bentham Science Publishers

Access to resources Recommend Favorite

Societal and Patient Burden of Fibromyalgia Syndrome

By Annemans Lieven  

PharmacoEconomics, Vol. 27, Iss. 7, 2009-07 ,pp. : 547-559

Adis International

Access to resources Recommend Favorite